"I have basic trust in you and your integrity as a professional manager, but if the company is all Mr. Lei's people, then even if I own 90% of the company, it is not my company.

"

"I believe you can understand what I mean. I prefer to be prepared in advance. There is no guarantee in the interests of just a relationship between a senior and a junior. You should know how big the market for endorphins is."

Zheng Li did not shy away from his purpose and his concerns about Cheng Gang and other people sent by Lei Jun.

After saying this, Cheng Gang's evaluation of Zheng Li was even higher. Preparation will lead to success, failure to do so will lead to failure.

As an eighteen-year-old young man, it is very difficult to keep a clear head when receiving an investment of 50 million from another party.

In addition, Cheng Gang was also very curious about Li Miaomiao, and what was so special about her that allowed Zheng Li to entrust her with important tasks.

"I understand your concerns, and I will prove my integrity with actions. As long as I am still with Kechuang Biotech, I will consider its interests."

"Also, Ms. Li, how much older am I than you? I usually call you Miaomiao. Do you think that's okay?"

Li Miaomiao replied: "No problem, Brother Cheng."

Cheng Gang secretly thought that the other party was also a quick person and could understand his subtext immediately:

"Miaomiao, let me first give you an overview of our company's structure. Currently, we only have the financial department, human resources department, legal department and R&D department, because our first product has not yet been officially launched."

"On the eve of our first drug being approved for marketing, we will set up a sales department to be responsible for the sales of the drug. The structure of a start-up biopharmaceutical company is roughly the same: finance, human resources, sales, legal affairs and research and development."

"Public relations, clinical trials, quality management, etc. will only be considered after the company grows."

"We will also have our own first-line standardized production base in the future."

"Like Hengrui Medicine, they have their own production bases in many places across the country, and they also have an integrated R&D and production base in Suzhou."

"In our company, Director Zheng is now in charge of the R&D department, and I am in charge of other departments, but Director Zheng has the right to make the decision."

"My personal suggestion to you is that you should mainly participate in personnel and financial work in the early stage, so that you can have a grasp of the overall situation of the company as soon as possible."

“After you have mastered the financial and human resources work, you can then have a deeper understanding of the business.”

After Cheng Gang finished speaking, Zheng Li nodded slightly. He knew that Cheng Gang's proposal had no selfish motives.

Li Miaomiao: "Thank you Brother Cheng for your opinion. I also think it is better to start with personnel and finance."

Zheng Li agreed: "Cheng Gang, you can make arrangements. I will continue to work downstairs."

...

Before a new drug can undergo formal clinical trials, it needs to conduct qualitative analysis and preclinical testing, and then obtain approval from the State Food and Drug Administration before it can be carried out in human clinical trials.

The qualitative analysis of endorphins is relatively simple, because there are previous papers for qualitative analysis, and Kechuang Biotech only needs to write a review.

Preclinical testing is relatively difficult, because before patent registration is approved, endorphins cannot be industrially mass-produced and can only be prepared through laboratory methods.

It took Kechuang Biotechnology one and a half months to complete the pre-clinical trial work and enter the waiting period for clinical trial approval.

Endorphins are very special. It is not a completely new drug. It was discovered very early, but it is not a generic drug because no pharmaceutical factory has mass-produced endorphins for sale before.

If it is a generic drug, there is no need to conduct clinical trials, only bioequivalence testing is required.

Domestic biopharmaceutical patent registration is faster than ordinary patent registration. In addition, endorphins are innovative drugs, so the registration process is even faster.

Within three months, the industrial production method of orphin was approved by the national patent, and the results of the first phase of clinical trials have also been released.

Phase I clinical trials generally only require 20 to 80 cases, and the Phase I clinical trial of endorphin was conducted on 100 cases.

Phase I clinical trials have verified the efficacy of endorphin injection and proved that its analgesic effect is better than that of morphine. In controlled experiments, it was proved that endorphins can still treat some patients who are resistant to analgesics.

Can work.

At the same time, the worldwide patent registration for Endorphin is almost completed.

This also resulted in Lei Jun’s first investment of 50 million being used up very little, and Kechuang Biotech was about to start a second round of investment.

In fact, as early as after the patent was approved, relevant investment institutions had already approached Cheng Gang and requested a visit to investigate.

As soon as the Phase I clinical trial report came out, many powerful institutions had already obtained it.

Investment institutions all believe that this is a business that is sure to make money without losing money. If you invest, you will make money.

At the same time, these investment institutions once again raised their evaluation of Zheng Li.

There is an insurmountable gap from laboratory products to industrial production, and it will take many years for many laboratory products to be commercialized.

Zheng Li was able to invent a laboratory method for producing endorphins and simplify the process to achieve industrialized mass production. Investment institutions also wanted to invest in scientific and technological innovations for people.

All of a sudden, investment institutions came in droves.

"Stephanie, you also know that I am only the general manager, and I can't say anything about Kechuang Biotech's second round of investment."

Cheng Gang looked helpless. The recent phone calls took up a lot of his energy, because many of them were acquaintances and it was difficult to refuse.

Investment institutions came to harass Zheng Li when they couldn't contact him. The person talking to him now is Stephanie Hui, the head of Goldman Sachs Group's investment department in Greater China.

"We are really optimistic about the prospects of Kechuang Biotech and hope to participate in Kechuang Biotech's second round of investment."

"Goldman Sachs can help Kechuang Biotech accelerate the progress of patent applications in Europe and the United States, and can help you complete clinical trials faster and obtain FDA approval."

"Goldman Sachs can help the growth of science and technology innovation in all aspects."

The conditions proposed by Stephanie are all urgently needed by Science and Technology Biotechnology.

Cheng Gang was unmoved. He smiled bitterly and said, "Stephanie, what you are talking about has been told to me by Young from IDG, Tuvia from Sequoia, Gee from Hillhouse, etc."

"Everything you said makes me very excited. I am willing to let you participate in the second round of venture capital. But I am not a big boss. I don't even have any shares. I am just a manager."

"I have no right to decide when the second round of investment will be launched, when to invest, or which institutions will be allowed to participate."

"Go and ask Mr. Lei from Da Mi. He has more say than me."

Stephanie smiled and said: "It seems that I'm disturbing you. I don't need you to give me any affirmative answer, nor do I need you to do anything that goes against the interests of your company."
Chapter completed!